MX2009012666A - Composicion para el tratamiento de enfermedades isquemicas de las extremidades que se componen de celulas madre derivadas de tejido adiposo. - Google Patents

Composicion para el tratamiento de enfermedades isquemicas de las extremidades que se componen de celulas madre derivadas de tejido adiposo.

Info

Publication number
MX2009012666A
MX2009012666A MX2009012666A MX2009012666A MX2009012666A MX 2009012666 A MX2009012666 A MX 2009012666A MX 2009012666 A MX2009012666 A MX 2009012666A MX 2009012666 A MX2009012666 A MX 2009012666A MX 2009012666 A MX2009012666 A MX 2009012666A
Authority
MX
Mexico
Prior art keywords
composition
stem cells
adipose tissue
treating ischemic
ischemic limb
Prior art date
Application number
MX2009012666A
Other languages
English (en)
Inventor
Hae Jung Han
Hang Young Lee
Hyo Eun Kim
Original Assignee
Rnl Bio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rnl Bio Co Ltd filed Critical Rnl Bio Co Ltd
Publication of MX2009012666A publication Critical patent/MX2009012666A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se divulgó en este documento una composición terapéutica celular para el tratamiento de enfermedades isquémicas en las extremidades inferiores, más específicamente, se divulgó una composición terapéutica celular para el tratamiento de enfermedades isquémicas que contienen células madre mesenquimatosas derivadas de tejido adiposo y sacarosa o manosa como un excipiente. La composición induce la angiogénesis alrededor de los vasos sanguíneos en las lesiones isquémicas de las extremidades inferiores, y de este modo es útil para tratar enfermedades isquémicas.
MX2009012666A 2007-05-25 2008-05-09 Composicion para el tratamiento de enfermedades isquemicas de las extremidades que se componen de celulas madre derivadas de tejido adiposo. MX2009012666A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020070050624A KR20080103637A (ko) 2007-05-25 2007-05-25 지방유래 줄기세포를 함유하는 사지말단부 허혈성 질환의세포치료용 조성물
PCT/KR2008/002614 WO2008147057A1 (en) 2007-05-25 2008-05-09 Composition for treating ischemic limb disease comprising stem cells derived from adipose tissue

Publications (1)

Publication Number Publication Date
MX2009012666A true MX2009012666A (es) 2010-02-18

Family

ID=40075249

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012666A MX2009012666A (es) 2007-05-25 2008-05-09 Composicion para el tratamiento de enfermedades isquemicas de las extremidades que se componen de celulas madre derivadas de tejido adiposo.

Country Status (8)

Country Link
US (1) US20100196329A1 (es)
EP (1) EP2162141B1 (es)
JP (1) JP5290281B2 (es)
KR (1) KR20080103637A (es)
CN (1) CN101711160B (es)
ES (1) ES2431816T3 (es)
MX (1) MX2009012666A (es)
WO (1) WO2008147057A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010000394A (es) 2007-11-30 2010-05-13 Rnl Bio Co Ltd Agente celular terapeutico para la incontinencia de la orina, que comprende celulas madres originadas de decidua o tejido adiposo.
CA2762584A1 (en) 2009-05-20 2010-11-25 Cardio3 Biosciences S.A. Pharmaceutical composition for the treatment of heart diseases
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
CN102920735A (zh) * 2012-11-14 2013-02-13 青岛奥克生物开发有限公司 一种间充质干细胞注射液及其制备方法和在制备治疗糖尿病药物中的应用
WO2014112607A1 (ja) * 2013-01-21 2014-07-24 国立大学法人名古屋大学 細胞製剤及び細胞の活性を高める方法
KR101583569B1 (ko) * 2013-05-15 2016-01-08 라정찬 정맥 투여용 줄기세포 조성물
JP2016008198A (ja) * 2014-06-24 2016-01-18 国立大学法人名古屋大学 間質性膀胱炎の治療
CN107072189B (zh) * 2014-07-08 2021-07-20 罗廷灿 用于改善干细胞稳定性的组合物
KR101613478B1 (ko) * 2014-09-22 2016-04-19 (주)안트로젠 중간엽줄기세포-하이드로겔을 함유하는 조성물 및 이의 제조방법
EP3271396B1 (en) 2015-03-20 2022-03-16 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
EP3922253A1 (en) 2016-01-15 2021-12-15 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
MY176088A (en) * 2016-07-26 2020-07-24 Cytopeutics Sdn Bhd A cell-based composition and use thereof for treatment of psoriasis and systemic lupus erythematosus
KR101980562B1 (ko) * 2017-01-16 2019-05-21 사회복지법인 삼성생명공익재단 옥살산염을 이용한 줄기세포능 향상 방법
GB2560933A (en) * 2017-03-28 2018-10-03 Glaxosmithkline Ip Dev Ltd Transduced cell formulation
JP6256786B1 (ja) * 2017-04-12 2018-01-10 学校法人福岡大学 不妊症の処置に用いられる医薬組成物およびその製造方法
EP3652305A2 (en) 2017-07-14 2020-05-20 Orbsen Therapeutics Limited Cd39 stromal stem cells methods of isolation and use
EP3677287B1 (en) 2017-08-30 2024-05-29 FUJIFILM Corporation Cell transplantation device and method for manufacturing same
JP6854904B2 (ja) 2017-08-30 2021-04-07 富士フイルム株式会社 血管新生剤およびその製造方法
CN112546070A (zh) * 2020-07-01 2021-03-26 陕西佰傲干细胞再生医学有限公司 间充质干细胞制剂及其制备方法和应用
JP7018527B1 (ja) 2020-12-16 2022-02-10 アニコム先進医療研究所株式会社 細胞の保存方法および細胞懸濁液
WO2023182609A1 (ko) * 2022-03-22 2023-09-28 가톨릭관동대학교산학협력단 지방 조직 유래 중간엽 줄기세포 및 인간 기질 혈관 분획을 포함하는 혈관신생 촉진용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045446A (en) * 1988-08-26 1991-09-03 Cryopharm Corporation Lyophilization of cells
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US6436704B1 (en) * 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
AU2001286221B2 (en) 2000-09-13 2006-09-28 Chugai Seiyaku Kabushiki Kaisha Remedies for ischemic diseases
WO2003059272A2 (en) * 2002-01-14 2003-07-24 Henry Ford Health System Materials from bone marrow stromal cells for use in forming blood vessels and producing angiogenic and trophic factors
CN100402654C (zh) 2003-02-19 2008-07-16 株式会社载体研究所 缺血疾病的治疗方法
MXPA06003088A (es) * 2003-09-17 2006-06-20 Macropore Biosurgery Inc Metodos para usar celulas regenerativas en el tratamiento de enfermedades vasculares perifericas y trastornos relacionados.
US20060045872A1 (en) * 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
JPWO2006134951A1 (ja) * 2005-06-13 2009-01-08 株式会社バイオマスター 脂肪由来幹細胞の長期培養増殖法
DE602005012081D1 (de) * 2005-07-29 2009-02-12 Univ Bonn Verfahren zur Isolierung von Stammzellen aus ein kissenformiges Gewebe der Zähne

Also Published As

Publication number Publication date
CN101711160A (zh) 2010-05-19
KR20080103637A (ko) 2008-11-28
CN101711160B (zh) 2013-04-24
WO2008147057A1 (en) 2008-12-04
JP2010528107A (ja) 2010-08-19
EP2162141A1 (en) 2010-03-17
US20100196329A1 (en) 2010-08-05
ES2431816T3 (es) 2013-11-28
EP2162141B1 (en) 2013-09-11
EP2162141A4 (en) 2011-01-26
JP5290281B2 (ja) 2013-09-18

Similar Documents

Publication Publication Date Title
MX2009012666A (es) Composicion para el tratamiento de enfermedades isquemicas de las extremidades que se componen de celulas madre derivadas de tejido adiposo.
UA99167C2 (ru) Лечение дегенерации межреберных дисков с использованием клеток, полученных из ткани пуповины человека
EP2183358A4 (en) PROCESS FOR THE PREPARATION OF DERMAL PAPER TISSUE EMPLOYING MESENCHYMAL STEM CELLS
EP2365816A4 (en) COMPOSITION WITH MECHANISM STAMMING CELLS OR BREATHING SOLUTION FOR MESENCHYM STAMMING CELLS FOR THE PREVENTION OR TREATMENT OF NERVOUS DISEASES
WO2007019107A3 (en) Adipose tissue stem cells, perivascular cells and pericytes
WO2009061447A3 (en) Use of umbilical cord blood in the treatment of premature birth complications
WO2008116157A3 (en) Mesenchymal stem cells and uses therefor
MX2010003019A (es) Celulas adherentes de los tejidos adiposo y de placenta y uso de las mismas en la terapia.
TW200637488A (en) Compositions containing botanical extracts rich in phlorizin and methods for using such compositions in blood glucose modification and to affect aging
IL212958B (en) Placental stem cells for the treatment of diseases, syndromes or conditions of the lungs
WO2007024441A3 (en) Compositions of cells enriched for combinations of various stem and progenitor cell populations, methods of use thereof and methods of private banking thereof
MX2013002381A (es) Celulas precursoras cd27 1 derivadas de medula osea para reparacion cardiaca.
GEP20146120B (en) Sglt-2 inhibitor for treating type i diabetes mellitus, type ii diabetes mellitus, impaired glucose tolerance or hyperglycemia
IL188378A0 (en) Use of adipose tissue derived stromal stem cells in treating fistula
WO2008013966A3 (en) Use of 8-quinolinol and its analogs to target cancer stem cells
MX2009007247A (es) Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos.
WO2008156685A3 (en) Tendon stem cells
WO2011038933A3 (en) Anti-hsv antibody
HK1205677A1 (en) Mesenchymal stem cells and uses therefor
CN103110936A (zh) 一种促进皮肤组织快速生长修复的生物制剂
WO2006091841A3 (en) Compositions and their uses directed to il-4r alpha
WO2006093860A3 (en) Method and composition for repairing heart tissue
WO2008134752A3 (en) Methods and compositions for the treatment of cancer
WO2014165723A3 (en) Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells
WO2007025229A3 (en) Compositions and their uses directed to hsp27

Legal Events

Date Code Title Description
FG Grant or registration